Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

• This article explains in straightforward terms whether AbbVie at around US$202 per share still offers value or whether most of the opportunity has already been priced in.

• The stock has recently been mixed, with a 4.1% decline over the last 7 days and a 1.8% decline over the last 30 days. It still shows returns of 12.8% over 1 year, 54.0% over 3 years, and 109.7% over 5 years.

• Recent coverage has focused on AbbVie’s position as a large US pharmaceuticals and biotech company and on how investors are reassessing established drug makers against other healthcare and AI themed opportunities. That context has put…